Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update May 12, 2023
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update March 27, 2023
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors March 20, 2023
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update August 15, 2022
